Par 10 Patterns of Dosing With Adalimumab Among Commercially Insured Patients

The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events

“…In contrast, all of the high-dose treatment groups in our meta-analyses initiated therapy at the high dose. Vishalpura et al 60 and Ollendorf et al 61 estimated that 10–24% of subjects receiving adalimumab may double their dose over a one-year period. Stern and Wolfe62 reported that the mean infliximab dose in clinical practice increases to 0.64 mg/kg per week after 2 years of therapy.…”